169 related articles for article (PubMed ID: 16452241)
1. The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice.
Carlo-Stella C; Di Nicola M; Turco MC; Cleris L; Lavazza C; Longoni P; Milanesi M; Magni M; Ammirante M; Leone A; Nagy Z; Gioffrè WR; Formelli F; Gianni AM
Cancer Res; 2006 Feb; 66(3):1799-808. PubMed ID: 16452241
[TBL] [Abstract][Full Text] [Related]
2. IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3.
Carlo-Stella C; Guidetti A; Di Nicola M; Lavazza C; Cleris L; Sia D; Longoni P; Milanesi M; Magni M; Nagy Z; Corradini P; Carbone A; Formelli F; Gianni AM
Cancer Res; 2007 Apr; 67(7):3269-75. PubMed ID: 17409435
[TBL] [Abstract][Full Text] [Related]
3. The in vitro biological activity of the HLA-DR-binding clinical IgG4 antibody 1D09C3 is a consequence of the disruption of cell aggregates and can be abrogated by Fab arm exchange.
Hansen K; Ruttekolk IR; Glauner H; Becker F; Brock R; Hannus S
Mol Immunol; 2009 Oct; 46(16):3269-77. PubMed ID: 19699529
[TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species.
De Milito A; Iessi E; Logozzi M; Lozupone F; Spada M; Marino ML; Federici C; Perdicchio M; Matarrese P; Lugini L; Nilsson A; Fais S
Cancer Res; 2007 Jun; 67(11):5408-17. PubMed ID: 17545622
[TBL] [Abstract][Full Text] [Related]
5. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma.
Bertolini F; Dell'Agnola C; Mancuso P; Rabascio C; Burlini A; Monestiroli S; Gobbi A; Pruneri G; Martinelli G
Cancer Res; 2002 Jun; 62(11):3106-12. PubMed ID: 12036921
[TBL] [Abstract][Full Text] [Related]
6. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia.
Zhang M; Zhang Z; Garmestani K; Goldman CK; Ravetch JV; Brechbiel MW; Carrasquillo JA; Waldmann TA
Cancer Res; 2004 Aug; 64(16):5825-9. PubMed ID: 15313926
[TBL] [Abstract][Full Text] [Related]
7. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
8. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.
Piloto O; Nguyen B; Huso D; Kim KT; Li Y; Witte L; Hicklin DJ; Brown P; Small D
Cancer Res; 2006 May; 66(9):4843-51. PubMed ID: 16651440
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of a monoclonal antibody against CD47 in xenograft models of human leukemia.
Uno S; Kinoshita Y; Azuma Y; Tsunenari T; Yoshimura Y; Iida S; Kikuchi Y; Yamada-Okabe H; Fukushima N
Oncol Rep; 2007 May; 17(5):1189-94. PubMed ID: 17390064
[TBL] [Abstract][Full Text] [Related]
10. 15d-PGJ2 induces apoptosis by reactive oxygen species-mediated inactivation of Akt in leukemia and colorectal cancer cells and shows in vivo antitumor activity.
Shin SW; Seo CY; Han H; Han JY; Jeong JS; Kwak JY; Park JI
Clin Cancer Res; 2009 Sep; 15(17):5414-25. PubMed ID: 19690198
[TBL] [Abstract][Full Text] [Related]
11. In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts.
Mollinedo F; de la Iglesia-Vicente J; Gajate C; Estella-Hermoso de Mendoza A; Villa-Pulgarin JA; de Frias M; Roué G; Gil J; Colomer D; Campanero MA; Blanco-Prieto MJ
Clin Cancer Res; 2010 Apr; 16(7):2046-54. PubMed ID: 20233887
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of 3,5,4'-trimethoxystilbene in COLO 205 cells and xenografts in SCID mice.
Pan MH; Gao JH; Lai CS; Wang YJ; Chen WM; Lo CY; Wang M; Dushenkov S; Ho CT
Mol Carcinog; 2008 Mar; 47(3):184-96. PubMed ID: 18085528
[TBL] [Abstract][Full Text] [Related]
13. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.
Li B; Shi S; Qian W; Zhao L; Zhang D; Hou S; Zheng L; Dai J; Zhao J; Wang H; Guo Y
Cancer Res; 2008 Apr; 68(7):2400-8. PubMed ID: 18381448
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice.
Flavell DJ; Warnes SL; Noss AL; Flavell SU
Br J Cancer; 2000 Dec; 83(12):1755-61. PubMed ID: 11104577
[TBL] [Abstract][Full Text] [Related]
15. Chronic high-dose morphine treatment promotes SH-SY5Y cell apoptosis via c-Jun N-terminal kinase-mediated activation of mitochondria-dependent pathway.
Lin X; Wang YJ; Li Q; Hou YY; Hong MH; Cao YL; Chi ZQ; Liu JG
FEBS J; 2009 Apr; 276(7):2022-36. PubMed ID: 19292871
[TBL] [Abstract][Full Text] [Related]
16. Glibenclamide exerts an antitumor activity through reactive oxygen species-c-jun NH2-terminal kinase pathway in human gastric cancer cell line MGC-803.
Qian X; Li J; Ding J; Wang Z; Duan L; Hu G
Biochem Pharmacol; 2008 Dec; 76(12):1705-15. PubMed ID: 18840412
[TBL] [Abstract][Full Text] [Related]
17. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
18. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.
Law CL; Gordon KA; Collier J; Klussman K; McEarchern JA; Cerveny CG; Mixan BJ; Lee WP; Lin Z; Valdez P; Wahl AF; Grewal IS
Cancer Res; 2005 Sep; 65(18):8331-8. PubMed ID: 16166310
[TBL] [Abstract][Full Text] [Related]
19. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
[TBL] [Abstract][Full Text] [Related]
20. An agonistic monoclonal antibody against DR5 induces ROS production, sustained JNK activation and Endo G release in Jurkat leukemia cells.
Chen C; Liu Y; Zheng D
Cell Res; 2009 Aug; 19(8):984-95. PubMed ID: 19468286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
